Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has partnered with Fred Hutchinson Cancer Research Center to develop therapeutics targeting an inherited form of muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD).
Subscribe to our email newsletter
The medicines resulting from the collaboration will inhibit the activity of protein that is wrongly expressed by the DUX4 gene and causes progressive muscle weakness and atrophy in FSHD patients.
Fred Hutchinson scientists’ research on genetic and disease mechanisms of FSHD forms the scientific basis for the collaboration with GSK.
As per the deal, the two organizations will work together to develop and bring potential therapeutics to the market.
Alliance represents the participation of first US institution in GSK’s Discovery Partnership with Academia (DPAc) program. Financial terms were kept confidential.
GSK DPAc global head Pearl Huang said the integration of drug-discovery knowledge with the in-depth disease knowledge of specialist academic groups can result in discovery and development of new medicines.
"We’re excited to be expanding our academic program in North America and are looking forward to working closely with scientists like Dr. Tapscott, whose deep understanding of disease biology will complement our own work in this field," Huang added.